Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART

Article Abstract:

Many protease inhibitors used to treat HIV infection inhibit P-glycoprotein. P-glycoprotein is found in many cells and is involved in drug uptake, distribution, and excretion.

Author: Vella, Stefano, Cauda, Roberto, Lucia, Mothanje Barbara, Rutella, Sergio, Leone, Giuseppe
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2001
Complications and side effects, HIV infection, Drug therapy, HIV infections

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Anti-HIV effects of chloroquine: Inhibition of viral particle glycosylation and synergism with protease inhibitors

Article Abstract:

The effects of chloroquine on glycosylation of HIV particles were tested in combination with protease inhibitors on HIV replication and on P-glycoprotein multidrug resistance protein-1. It was found that the inhibitory effects of chloroquine on HIV glycosylation are associated with synergistic in combination with protease inhibitors and the chloroquine / protease combination exerts inhibitory effects on P-glycoprotein and multidrug resistance protein-1 function.

Author: Cauda, Roberto, Rutella, Sergio, Perno, Carlo Federico, Rastrelli, Elena, Savarino, Andrea, Lucia, Mothanje B., Golotta, Caterina, Morra, Emanuella, Tamburrini, Enrica, Boelaert, Johan R., Sperber, Kirk
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2004
United States, Glycosylation, Dosage and administration, Drug use, Chloroquine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Atazanavir inhibits p-glycoprotein and multidrug resistance-associated protein efflux activity

Article Abstract:

An investigation on whether atazanavir (ATV) alone or in combination with other HIV-protease inhibitors (PIs) inhibits P-glycoprotein (p-gp) and multi-drug resistance-associated protein (MRP) function in normal peripheral blood lymphocytes (PBLs) is presented. Results reveal that the ATV is a possible substrate for P-gp and MRP in HIV-target cells such as normal PBLs and, like other PIs, competitively inhibits their efflux activity in a dose-dependent manner.

Author: Cauda, Roberto, Lucia, Mothanje Barbara, Rutella, Sergio, Rastrelli, Elena, Savarino, Andrea, Golotta, Caterina
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
Product development, Drug therapy, Combination, Combination drug therapy, Atazanavir (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Protease inhibitors, Glycoproteins, Research
Similar abstracts:
  • Abstracts: Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1 infected patients
  • Abstracts: Magnesium sulfate induces translocation of protein kinase C isoenzymes alpha and delta in myometrial cells from pregnant women
  • Abstracts: Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population
  • Abstracts: Young guns: three members of bodybuilding's Generation X reveal the latest tricks of the arms trade. Gun show
  • Abstracts: The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV- 1- infected patients
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.